Se desexas distinguir vos teus produtos, servizos ou ambos os dous doutra empresa, é posible que necesites unha marca ou nome comercial. Descobre que son, en que consiste ou seu procedemento de rexistro e que implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Se tes un novo dispositivo, produto ou procedemento que resolva un problema técnico ou teña unha vantaxe práctica, existen distintas formas de protexelo en España e noutros países. Descobre como facelo.
A túa innovación reside na estética, a ornamentación ou a aparencia do teu produto? Protéxea mediante un deseño industrial. Descobre que dereitos confire ou rexistro e como realizar a tramitación.
As patentes publicadas en todo ou mundo son unha valiosa fonte de información científica, técnica e comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ése emprendedor/a ou unha empresa e queres potenciar e mellorar a rendibilidade do teu negocio protexendo de forma adecuada vos activos intangibles dá túa organización, neste espazo atoparás ou necesario.
141
resultados
Última actualización
23/08/2025 [06:58:00]
Resultados 50 a 75 de 141
Resumen de: AU2024209583A1
The disclosure describes devices and methods for insertion and delivery of insulin or an insulin analog formulation and measurement of subcutaneous glucose concentration. A device for delivery of insulin or an insulin analog formulation and measurement of subcutaneous glucose concentration, may comprise: (a) a tube comprising a proximal end and a distal end, wherein the proximal end is in fluid communication with a source of the insulin or insulin analog formulation, and wherein the distal end is configured to deliver the insulin or insulin analog formulation subcutaneously; (b) a glucose sensor disposed along a central axis of the tube; and (c) a penetrating body disposed along the central axis of the tube, wherein the penetrating body comprises a cross-sectional area no more than a cross-sectional area of the glucose sensor.
Resumen de: US2025239350A1
Provided is a personalized artificial intelligence-based insulin dose determination system includes an interface layer capable of communicating with the insulin pump and the continuous blood glucose system, and signal-processing information from the insulin pump and the continuous blood glucose system, a control layer receiving the signal-processed information from the interface layer and generating output information associated with an insulin infusion amount, an outer safety layer determining whether or not the output information generated from the control layer satisfies a preset threshold condition, and delivering the output information to the interface layer when the output information satisfies the preset threshold condition, and a personalized safety layer receiving prescription information including Total Daily Dose of Insulin (TDD) information of the user from the outside to determine a personalized safety control variable, and transmitting the determined control variable as an input variable of the control layer.
Resumen de: US2025235606A1
The invention discloses a closed-loop artificial pancreas insulin infusion control system, including: a detection module and an infusion module, a detection control unit is set in the detection module, an infusion control unit is set in the infusion module, and at least one calculation control unit is set in the detection module and the infusion module for calculating insulin infusion information and/or further processing of different insulin infusion information. Therefore, the closed-loop artificial pancreas insulin infusion control system can automatically switch the control unit according to different situations to avoid affecting the user experience due to the failure of a module or even bringing safety risks to the user, and to avoid replacing the whole device when only part of the function of some components fails, and to improve the utilization rate of each component of the closed-loop artificial pancreas.
Resumen de: US2025235614A1
A closed-loop artificial pancreas insulin infusion control system is provided. The system includes a detection module configured to detect the current blood glucose level G continuously, a program module connected to the detection module and preset with a hybrid artificial pancreas algorithm, used for calculating the insulin infusion amount required by the user, the hybrid artificial pancreas algorithm includes a cPID algorithm and/or a cMPC algorithm, where the input of the cPID algorithm is the intermediate value of the MPC algorithm, and the input of the cMPC algorithm is the output value of the PID algorithm, and an infusion module connected to the program module and controlled by the program module to infuse insulin according to the insulin infusion amount calculated by the hybrid artificial pancreas algorithm.
Resumen de: WO2025154863A1
The present invention relates to a method for increasing the accuracy and precision of a non-invasive blood glucose measurement apparatus and, more specifically, to a method for increasing the accuracy and precision of a non-invasive blood glucose measurement apparatus, wherein, in order to increase the accuracy and precision of quantitative analysis of the non-invasive blood glucose measurement apparatus, an algorithm having a qualitative analysis and an algorithm of quantitative analysis are combined to enhance blood glucose prediction values. To this end, the present invention comprises: a step of starting measurement after making contact with the capillary system in the skin of the body by using a selected wavelength band related to blood glucose; a skin irradiation step of sequentially irradiating the blood vessels in the skin with monochromatic light corresponding to each of visible light and near-infrared light; and a detector signal step of a detector receiving signals from the monochromatic light in the skin irradiation step, wherein the detector signal step is completed, and the accuracy and precision of the non-invasive blood glucose measurement apparatus are increased.
Resumen de: US2025235675A1
A monitoring system is provided. The monitoring system includes a controller and either a shunt device, an externally-communicating catheter, and/or a fluid retention device. The shunt device and catheter are configured to address fluid movement such as ascites and pleural effusions. Each of the shunt device and catheter include a plurality of sensors that communicate with the controller positioned external to a body of a subject. The plurality of sensors are configured to output a signal indicative of a total volume, a glucose amount, or an oxygenation within a fluid flowing in contact within or surrounding the shunt device or the catheter.
Resumen de: WO2024055249A1
A management device for displaying glucose information. The screen of the management device is divided into the plurality of display areas, at least comprising a first display area for displaying the status of the management device, a second display area for displaying real-time glucose information, and a third display area for displaying historical glucose concentration information. The user can intuitively and easily get the glucose information in the body.
Resumen de: CN119856162A
Systems, devices, and methods are provided for incorporating a drug delivery device into an integrated management system. The integrated management system may be an integrated diabetes management system and may include a glucose monitor, a connected insulin pen, and software. An integrated management system may generate a plurality of reports, which may include data related to analyte levels (e.g., glucose levels) and delivered drugs (e.g., delivered insulin). The integrated system may also include a mode in which certain types of data are no longer shared and/or stored if the user does not log in the account. The type of data shared and/or stored when the user does not log in the account may be different from the type of data shared and/or stored when the user logs in the account.
Resumen de: EP4588437A2
The present disclosure relates to a diabetes management system and a method for the same. The system includes a pump device and a controller, where the controller is in electrical communication with a drive system for controlling dispensation of insulin from an insulin cartridge. The controller, over a first diurnal time period, communicates electrical control signals to the drive system to cause insulin to be dispensed based on a baseline basal insulin rate that is stored. The controller also receives at least blood glucose data to control dispensation of insulin in amounts variable from the baseline basal insulin rate. Additionally, the controller modifies the baseline basal insulin rate that is stored for a second diurnal time period that is at least 20 hours after the first diurnal period, based on an amount of insulin actually dispensed during the first diurnal time period.
Resumen de: EP4588494A1
The invention discloses a drug delivery system with graphical user interface comprises detection device, for detecting the blood glucose level of the user; an infusion device, for infusing a drug into the user's body; and a control device, wirelessly communicated with the detection device and the infusion device, the control device controlling the drug delivery of the infusion device, and the control device provided with a graphical user interface, the graphical user interface comprising a main screen, the main screen comprising an insulin information display area and a blood glucose information display area, wherein the insulin information display area comprising insulin infusion status information, the graphical user interface displays the insulin infusion status information in a graphical and/or textual manner, to facilitate the user to intuitively know the insulin infusion status information and blood glucose information at that time.
Resumen de: US2025229023A1
The invention discloses a closed-loop artificial pancreas insulin infusion control system, including: detection module, an infusion module and an electronic module, the detection module, the infusion module and the electronic module all equipped with a control unit, and each control unit is preset with a first algorithm, a second algorithm and a third algorithm correspondingly. When different priority conditions are met, different modules determine the current insulin infusion information. Therefore, the closed-loop artificial pancreas insulin infusion control system can automatically switch control units according to different situations, so as to avoid affecting the user experience and even bringing security risks to users when a module set with the control unit cannot work normally.
Resumen de: US2025229024A1
Techniques related to temporary setpoint values are disclosed. The techniques may involve causing operation of a fluid delivery device in a closed-loop mode for automatically delivering fluid based on a difference between a first setpoint value and an analyte concentration value during operation of the fluid delivery device in the closed-loop mode. Additionally, the techniques may involve obtaining a second setpoint value. The second setpoint value may be a temporary setpoint value to be used for a period of time to regulate fluid delivery, and the second setpoint value may be greater than the first setpoint value. The techniques may further involve causing operation of the fluid delivery device for automatically reducing fluid delivery for the period of time based on the second setpoint value.
Resumen de: US2025232078A1
Examples of a simulation framework are provided to evaluate time varying systems using a piecewise linear time invariant simulation (PLIS) approach. The simulation framework can be configured for an artificial pancreas wireless network system that controls blood glucose in Type 1 Diabetes patients with time varying properties such as physiological changes associated with psychological stress and meal patterns.
Resumen de: US2025229018A1
A drug infusion device with integrated power supply includes a drug reservoir, used for accommodating the drug to be infused, provided with a piston and a screw; a driving wheel, connected with the screw, driving the screw to push the piston forward by rotation; a power supply, used to supply power to the infusion device, including a power supply shell, a power supply cell, electrolyte and a cover plate; and a case, including an upper case and a lower case, for accommodating the drug reservoir, the drive wheel and the power supply. The power supply shell is integrated with the lower and/or the cover plate is integrated with the upper case.
Resumen de: WO2025151241A1
The wireless heart telemetry device and accompanied patient monitoring system provides continuous patient monitoring in a comfortable and streamlined design for healthcare settings by providing electrocardiogram (ECG) physiological data in a wireless skin patch device. The wireless heart telemetry device integrates into a full patient monitoring system to provide additional vital physiological patient data in wireless system. This additional physiological data includes pleth, blood oxygen saturation (SPO2), blood pressure, heart rate, respiration rate, temperature, and glucose. The pulse oximeter portion of the system includes mechanical designs such as a finger clip, ring, and bracelet design for enhanced usage, accuracy, and comfort. Another example embodiment of the pulse oximeter portion of the system includes fall detection, bed alarm, and location monitoring services. An additional example embodiment includes a melanin bias reducing pulse oximeter.
Resumen de: WO2025150098A1
This non-invasive measurement device comprises: a light source unit 10 that emits excitation light; an irradiation optical system 11 that irradiates skin tissue 2 with the excitation light; a detection optical system 12 that collects Raman-scattered light from the skin tissue 2; a spectroscope 13 that separates the Raman-scattered light; and an analysis device 14 that analyzes a spectroscopic signal obtained as a result of the separation by the spectroscope so as to measure blood sugar level. The irradiation optical system 11 forms the excitation light into minute beam spots in a dot pattern and irradiates the skin tissue 2 obliquely with the excitation light.
Resumen de: WO2025150099A1
A non-invasive measurement device according to the present invention comprises: a light source unit 10 which emits excitation light; an irradiation optical system 11 which irradiates skin tissue 2 with the excitation light; a detection optical system 13 which collects Raman scattered light from the skin tissue 2; a spectroscope 14 which disperses the Raman scattered light; and an analysis device 15 which analyzes a spectral signal obtained as a result of the dispersion by the spectroscope 14 and measures a blood glucose level. The irradiation optical system 11 shapes the cross section of the excitation light into a ring and irradiates the skin tissue 2 with the excitation light, and the detection optical system 13 is positioned to detect light returned from a part of the skin tissue 2 that is the central portion of a ring-shaped beam spot irradiated on the skin tissue 2.
Resumen de: US2025230174A1
Glucose-sensing luminescent dyes, polymers, and sensors are provided. Additionally, systems including the sensors and methods of using these sensors and systems are provided.
Resumen de: US2025228501A1
Provided herein are systems and methods of predicting and managing blood glucose levels in individuals, including systems and methods of predicting blood glucose levels based on predicted future glucose factors. Also provided herein are systems and methods of recommending glucose interventions based thereon. It is appreciated by the present disclosure that it is better to prevent extreme blood glucose levels before they occur than merely detecting such levels when they occur. Accordingly, the systems and methods described herein utilized a combination of contextual information and current time glucose measurements/estimates to predict the likelihood of different scenarios that might lead to such extreme levels before they occur.
Resumen de: US2025228475A1
One embodiment is a method for implementing a cloud-based portable miniaturized system for performing non-invasive blood glucose level measurement in real time. The method includes using an optical source to emit optical radiations at certain wavelengths through breath in an air collection chamber; receiving the emitted optical transmissions at a photodetector; converting the received optical transmissions to digital data; accumulating the digital data for a first time period; and periodically transmitting the accumulated digital data to a cloud service for further processing.
Resumen de: US2025228478A1
Disclosed are devices, systems and methods for in vivo monitoring of localized environment conditions within a patient user by measuring analytes, including glucose, oxygen, and/or other analytes. In some aspects, a sensor device includes a wafer-based substrate, at least one electrochemical sensor two-electrode contingent including a working electrode and a reference electrode on the substrate and configured to detect a target analyte in a body fluid when the sensor device is deployed within a subject's body, where the working electrode is functionalized by a chemical layer configured to facilitate a reaction involving the target analyte that produces an electrical signal; and an electronics unit in communication with the electrochemical sensor electrode contingent to transmit the electrical signal to an external processor.
Resumen de: EP4585239A2
An insulin infusion system is provided with a manual insertion device having a dual retraction spring (230) configuration for automatic introducer needle (222) retraction. A button (200) of the insertion device is used to insert the introducer needle (222) and catheter (202), and once the introducer needle (222) and catheter (202) have been fully inserted, a rotating engagement releases the dual retraction springs (230) such that the introducer needle (222) automatically retracts, leaving the catheter (202) in the body of the user. An end of the introducer needle (222) remains in the inserted catheter (202) and/or in the septum (206) of the inserted catheter (202) to provide an uninterrupted fluid path.
Resumen de: AU2023377269A1
A method, system, and computer-readable medium are provided for an Automated Insulin Delivery (AID) system in which Model Predictive Control (MPC) thereof implements weighting of glucose target error relative to corresponding predicted blood glucose (BG) levels according to insulin on board (IOB). Accordingly, basal insulin infusion and available additional bolusing each in connection with glycemic disturbances such as unannounced meals can be proximally administered to maintain time in range (TIR) without incurring insulin stacking.
Resumen de: US2025221643A1
Multiple enzymes may be present in one or more active areas of an electrochemical analyte sensor for detecting one or more different analytes. In particular, an analyte sensor may comprise a sensor tail configured for insertion into a tissue and one or more working electrodes having a glucose-responsive active area and an ethanol-responsive active area to detect glucose and ethanol in vivo.
Nº publicación: US2025226076A1 10/07/2025
Solicitante:
UNIV BERN [CH]
DEBIOTECH S A [CH]
UNIVERSIT\u00C4T BERN,
DEBIOTECH S.A
Resumen de: US2025226076A1
An aspect of the invention provides a method and a product for determining a modification of the therapy management by using a processor unit which retrieves few data related to the blood glucose measurement performed over a predetermined time period; retrieve the medication delivery parameter executed by the delivery device over said predetermined time period; retrieve from the memory data associated to the CIR of the patient; and determine a modification to the therapy based on at least a part of the retrieved data.
BOPI
Sede Electrónica
